Publications

Journal Article
Research Support, Non-U.S. Gov't
Ppublish 16 citations
Electronic publication date
March 30, 2016

View on Pubmed.gov 26084608 | View on doi.org 10.1007/s13277-...

HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer.

Search for publications in this journal Tumour Biol - 36(11):9039-47

  • Yirong Xu

    Search for this expert
    1
  • Zhenwen Chen

    Search for this expert
    2
  • Guangheng Zhang

    Search for this expert
    2
  • Yanfeng Xi

    Search for this expert
    3
  • Ruifang Sun

    Search for this expert
    3
  • Fei Chai

    Search for this expert
    2
  • Xiaogang Wang

    Search for this expert
    2
  • Jianhong Guo

    Search for this expert
    3
  • Lin Tian

    Search for this expert
    4

Abstract

High mobility group box 1 (HMGB1) is associated with tumor progression and a poor prognosis; microtubule-associated protein 1 light chain 3 (LC3) plays a critical role in autophagy. However, the roles of HMGB1 and LC3 in squamous cervical cancer (SCC) remain unclear. An array of 166 early-stage SCC, 62 cervical intraepithelial neoplasia (CIN), and 50 normal cervical tissue samples was assessed. HMGB1 and LC3 protein levels were examined by immunohistochemistry, and the associations of HMGB1 and LC3 levels with clinicopathological characteristics evaluated, to assess their prognosis significance. High nuclear HMGB1 levels were detected in 72.9% SCC cases; 16% cases showed cytoplasmic expression of HMGB1 in cancer cells with low nuclear expression. Interestingly, HMGB1 levels in SCC samples were significantly higher than CIN and control specimens, while lower LC3 expression was found in SCC samples (P < 0.001). Nuclear HMGB1 expression was weakly negatively correlated to LC3 amounts (r = -0.254, P = 0.001). High nuclear HMGB1 levels were associated with vascular metastasis (P < 0.05). In addition, cytoplasmic HMGB1 expression was associated with lymph node metastasis (P < 0.05). Furthermore, high nuclear HMGB1 levels and cytoplasmic HMGB1 expression predicted poor overall survival (OS) and disease-free survival (DFS). Meanwhile, high LC3 expression was associated with favorable prognosis. Multivariate analysis showed that both nuclear and cytoplasmic HMGB1 expressions were independent prognostic factors for overall- and disease-free survival, along with nodule metastasis. HMGB1 overexpression plays a significant role in SCC progression. Both nuclear and cytoplasmic HMGB1 are independent factors for poor prognosis in early-stage SCC.

References

Methods Cell Biol. 1977;16:257-67

Cell Metab. 2014 Mar 4;19(3):539-47

Cell. 2005 Jan 28;120(2):237-48

Oncol Rep. 2009 Sep;22(3):535-9

Cited by 16 citations (total)

Journal Article Review

HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity.

Electronic publication date August 9, 2020

Search for publications in this journal Onco Targets Ther

Yin Liao [...] Jingbo Wu et al.

Radiotherapy (RT) is a mainstay of cancer treatment. Recent studies have shown that RT not only directly induces cell death...

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't

No association between HMGB1 polymorphisms and cancer risk: evidence from a meta-analysis.

Electronic publication date June 25, 2019

Search for publications in this journal Biosci Rep

Xing-Yan Li [...] Jin-Min Zhao et al.

The aim of the present study was to determine whether High mobility group box 1 (HMGB1) polymorphism was associated with...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances